ArticleNature reviews. Clinical oncology2020
Imatinib and the long tail of targeted drug development.
Article in Nature reviews. Clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review.Targeted oncology · 2024Pooled it
- Assessing patient risk, benefit, and outcomes in drug development: a decade of sorafenib clinical trials.European journal of clinical pharmacology · 2026Review
- Post-marketing safety signals of imatinib: pharmacovigilance insights from the FDA Adverse Event Reporting System (FAERS) and implications for clinical practice.European journal of clinical pharmacology · 2025Article
- Adapting systems biology to address the complexity of human disease in the single-cell era.Nature reviews. Genetics · 2025Review
- An evaluation of selinexor's clinical trial portfolio: a cross-sectional study.Therapeutic advances in hematology · 2025Article
- A novel strategy to bind pyrimidine sulfonamide derivatives with odd even chains: exploration of their design, synthesis and biological activity evaluation.Molecular diversity · 2024Article
- Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials.Cancer medicine · 2024Article
- Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials.BMJ oncology · 2024Article
- Immunotherapies targeting tumor vasculature: challenges and opportunities.Frontiers in immunology · 2023Review
- Quantifying Patient Investment in Novel Neurological Drug Development.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Article
- Review
- Promises and challenges of adoptive T-cell therapies for solid tumours.British journal of cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
31649355What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.